The FMD-dependent reduction in blood insulin, IGF-1 and leptin, which consequently leads to the inhibition of the PI3K/AKT, mTOR pathways, can also enhance the efficacy of estrogen therapies against estrogen receptor positive (ER+) breast cancer [141]. This evidence concerns the gene IGF1 and breast carcinoma.